Table 1.
All | Self-reported SAB* 6–19 weeks’gestation | Ongoing pregnancies¶ at 20 weeks’ gestation | Participants with ongoing pregnancy at contact prior to 20 weeks’ gestation | Other pregnancy loss 6–19 weeks gestation | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Characteristics | n | % | n | %± | N | %± | n | %± | n | %± |
Total | 2456 | 165 | 2022 | 253 | 16 | |||||
Age at 1st eligible vaccine dose (years) | ||||||||||
20–29 | 432 | 17.6 | 23 | 13.9 | 343 | 17.0 | 64 | 25.3 | 2 | 12.5 |
30–34 | 1205 | 49.1 | 71 | 43.0 | 1020 | 50.4 | 108 | 42.7 | 6 | 37.5 |
35–39 | 693 | 28.2 | 54 | 32.7 | 561 | 27.7 | 72 | 28.5 | 6 | 37.5 |
40+ | 126 | 5.1 | 17 | 10.3 | 98 | 4.8 | 9 | 3.6 | 2 | 12.5 |
Race and Hispanic origin | ||||||||||
Non-Hispanic Black | 35 | 1.4 | 5 | 3.0 | 23 | 1.1 | 6 | 2.4 | 1 | 6.3 |
Non-Hispanic White | 1923 | 78.3 | 113 | 68.5 | 1613 | 79.8 | 185 | 73.1 | 12 | 75.0 |
Hispanic | 220 | 9.0 | 21 | 12.7 | 159 | 7.9 | 39 | 15.4 | 1 | 6.3 |
Non-Hispanic American Indian/Alaskan Native | 7 | 0.3 | 0 | 0.0 | 6 | 0.3 | 1 | 0.4 | 0 | 0.0 |
Non-Hispanic Native Hawaiian/Pacific Islander | 8 | 0.3 | 0 | 0.0 | 6 | 0.3 | 2 | 0.8 | 0 | 0.0 |
Non-Hispanic Asian | 210 | 8.6 | 17 | 10.3 | 179 | 8.9 | 13 | 5.1 | 1 | 6.3 |
Non-Hispanic multiple races | 48 | 2.0 | 7 | 4.2 | 34 | 1.7 | 6 | 2.4 | 1 | 6.3 |
Missing | 5 | 0.2 | 2 | 1.2 | 2 | 0.1 | 1 | 0.4 | 0 | 0.0 |
Self-reported vaccine priority group | ||||||||||
Non-healthcare essential worker | 148 | 6.0 | 6 | 3.6 | 110 | 5.4 | 30 | 11.9 | 2 | 12.5 |
Healthcare personnel† | 2180 | 88.8 | 149 | 90.3 | 1822 | 90.1 | 196 | 77.5 | 13 | 81.3 |
Vaccine type | ||||||||||
Moderna | 1162 | 47.3 | 85 | 51.5 | 944 | 46.7 | 126 | 49.8 | 7 | 43.8 |
Pfizer-BioNTech | 1294 | 52.7 | 80 | 48.5 | 1078 | 53.3 | 127 | 50.2 | 9 | 56.3 |
Number of vaccine doses reported | ||||||||||
1 | 245 | 10.0 | 39 | 23.6 | 183 | 9.1 | 18 | 7.1 | 5 | 31.3 |
2 | 2211 | 90.0 | 126 | 76.4 | 1839 | 90.9 | 235 | 92.9 | 11 | 68.8 |
Timing of Dose 1 | ||||||||||
Preconception** | 380 | 15.5 | 56 | 33.9 | 212 | 10.5 | 106 | 41.9 | 6 | 37.5 |
First trimester (>=2 and <14 weeks) | 1230 | 50.1 | 107 | 64.8 | 971 | 48.0 | 142 | 56.1 | 10 | 62.5 |
Second trimester (>=14 and <20 weeks¶¶) | 846 | 34.4 | 2 | 1.2 | 839 | 41.5 | 5 | 2.0 | 0 | 0.0 |
Timing of Dose 2 (n=2211) | ||||||||||
Preconception** | 188 | 8.5 | 19 | 11.5 | 116 | 5.7 | 50 | 19.8 | 3 | 18.8 |
First trimester (>=2 and <14 weeks) | 885 | 40.0 | 91 | 55.2 | 642 | 31.8 | 145 | 57.3 | 7 | 43.8 |
Second trimester (>=14 and <28 weeks) | 1125 | 50.9 | 4 | 2.4 | 1081 | 53.5 | 40 | 15.8 | 0 | 0.0 |
After pregnancy outcome | 13 | 0.6 | 12 | 7.3 | 0 | 0.0 | 0 | 0.0 | 1 | 6.3 |
Comorbidities and past medical history | ||||||||||
Obesity±± | 432 | 17.6 | 34 | 20.6 | 340 | 16.8 | 57 | 22.5 | 1 | 6.3 |
Pre-existing diabetes | 27 | 1.1 | 2 | 1.2 | 23 | 1.1 | 2 | 0.8 | 0 | 0.0 |
Prior SAB | 675 | 27.5 | 59 | 35.8 | 549 | 27.2 | 65 | 25.7 | 2 | 12.5 |
1 Prior SAB | 452 | 67.0 | 33 | 20.0 | 373 | 18.4 | 44 | 17.4 | 2 | 12.5 |
2 or more Prior SABs | 223 | 33.0 | 26 | 15.8 | 176 | 8.7 | 21 | 8.3 | 0 | 0.0 |
Spontaneous abortion
Includes 19 live births, 5 stillbirths, 2 induced abortions after 20 gestational weeks, and 1996 pregnancies ongoing as of last interview
Column percentages provide among each pregnancy outcome/status; these should not be interpreted as risk estimates
Any person serving in a healthcare setting who has the potential for direct or indirect exposure to patients or infectious materials
Preconception defined as 4 weeks before last menstrual period up to 2 weeks after
Second trimester vaccination for dose 1 limited to receipt at less than 20 weeks’ gestation per study criteria
12 cases missing information to determine body mass index for obesity